Michal Barzily-Rokni
Overview
Explore the profile of Michal Barzily-Rokni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
3904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abu Shtaya A, Nathan S, Kedar I, Friedman E, Half E, Lidzbarsky G, et al.
Fam Cancer
. 2024 Nov;
24(1):6.
PMID: 39546165
Deciphering the spectrum and founder disease-causing variants (DCVs) in specific populations can shape and facilitate the diagnostic process of Lynch Syndrome (LS). The aim of this report was to comprehensively...
2.
Freeman S, Sade-Feldman M, Kim J, Stewart C, Gonye A, Ravi A, et al.
Cell Rep Med
. 2022 Mar;
3(2):100500.
PMID: 35243413
Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve...
3.
Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al.
Cell
. 2019 Jan;
176(1-2):404.
PMID: 30633907
No abstract available.
4.
Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al.
Cell
. 2018 Nov;
175(4):998-1013.e20.
PMID: 30388456
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors...
5.
Zhang G, Wu L, Mender I, Barzily-Rokni M, Hammond M, Ope O, et al.
Clin Cancer Res
. 2018 Mar;
24(19):4771-4784.
PMID: 29563139
Telomerase promoter mutations are highly prevalent in human tumors including melanoma. A subset of patients with metastatic melanoma often fail multiple therapies, and there is an unmet and urgent need...
6.
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, et al.
Cell Rep
. 2017 Nov;
21(7):1953-1967.
PMID: 29141225
Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further...
7.
Jenkins R, Aref A, Lizotte P, Ivanova E, Stinson S, Zhou C, et al.
Cancer Discov
. 2017 Nov;
8(2):196-215.
PMID: 29101162
systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination...
8.
Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J, et al.
Nat Commun
. 2017 Oct;
8(1):1136.
PMID: 29070816
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain...
9.
Geller L, Barzily-Rokni M, Danino T, Jonas O, Shental N, Nejman D, et al.
Science
. 2017 Sep;
357(6356):1156-1160.
PMID: 28912244
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycytidine) into its...
10.
Konieczkowski D, Johannessen C, Abudayyeh O, Kim J, Cooper Z, Piris A, et al.
Cancer Discov
. 2014 Apr;
4(7):816-27.
PMID: 24771846
Unlabelled: Most melanomas harbor oncogenic BRAF(V600) mutations, which constitutively activate the MAPK pathway. Although MAPK pathway inhibitors show clinical benefit in BRAF(V600)-mutant melanoma, it remains incompletely understood why 10% to...